REGULATORY

• Japan Approves J-TEC’s Cell Sheet for Vitiligo, Aurion’s Bullous Keratopathy Therapy
  March 22, 2023

• Oral Abortion Pill Mefeego Up for Another Round of Panel Reviews on March 24
  March 20, 2023

• Expert Panel Discusses 2% Buffer Zone, Member Floats “Regional Index”
  March 20, 2023

• Expert Panel Seeks Revision of Drug Pricing Rules to Stabilize Supplies
  March 20, 2023

• Expert Panel Talks over Yakkasa, Revamp of Price Revision Method; Fixed Margin, Claw-Back Mooted
  March 20, 2023

• 97 Health Damages Reported for Kymriah in Japan: April-September
  March 17, 2023

• Japan to Add Purchased Doses of Paxlovid, Xocova to Govt Stockpile
  March 17, 2023

• Health Minister Vows to Make Use of Govt-Purchased Xocova
  March 17, 2023

• Japan Damage Relief Panel Recognizes 11 More Deaths Possibly Tied to COVID Jabs
  March 16, 2023

• PMDA Sets Target Duration of SaMD Priority Reviews to 6 Months in FY2024 Plan
  March 14, 2023

• Japan Safety Panels Recognize 1st Death Tied to COVID Vaccine
  March 13, 2023

• LDP Lawmakers Call on Local Governments to Urge HPV Vaccinations
  March 13, 2023

• Japan to Offer COVID Drugs for Free until September-End
  March 13, 2023

• Japan Eager to Resolve Lag in Pediatric Cancer Drug Development: Minister
  March 10, 2023

• AbbVie’s Parkinson’s Drug, Kaken’s Eschar Remover Skip March Listing
  March 9, 2023

• Chuikyo OKs Listing of Mounjaro, Libtayo, Imjudo; 30 Billion-Plus Peak Sales for Lilly Med
  March 9, 2023

• Paxlovid Priced at 99,027 Yen per 5-Day Treatment; 5% Premium on Lagevrio Price
  March 9, 2023

• Xocova Priced at 51,851 Yen per Course with Peak Sales Put at 19.2 Billion Yen
  March 9, 2023

• Tagrisso Faces 10.5% Slash in June in Its Second Re-Pricing
  March 9, 2023

• Emgality, Veklury, and More to Get Lower Prices in June: CEA Scheme
  March 9, 2023

ページ

• « 先頭
• ‹ Prev
• …
• 90
• 91
• 92
• 93
• 94
• 95
• 96
• 97
• 98
• …
• Next ›
• 最終 »